Effectiveness and safety of bulevirtide monotherapy 2 mg/die in hdv patients with compensated cirrhosis and clinically significant portal hypertension

E. Degasperi,A. Loglio,S.C. Uceda Renteria,D. Sambarino,M. Borghi,R. Perbellini,C. Scholtes,F. Facchetti,M. Fraquelli,A. Costantino, C. Orsini,F. Ceriotti,F. Zoulim,P. Lampertico

Digestive and Liver Disease（2022）

引用 0|浏览9

暂无评分

摘要

Introduction: Bulevirtide (BLV) has been recently approved for the treatment of HDV-related chronic hepatitis or compensated cirrhosis in Europe, but its effectiveness and safety in patients with advanced cirrhosis and severe portal hypertension are still unknown.

查看译文

关键词

bulevirtide monotherapy,hdv patients,cirrhosis,hypertension

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要